UTAA91 injection for difficult rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe rheumatoid arthritis that hasn't gotten better with standard treatments.
- Your doctor expects you to live at least 3 more months.
- Your liver, kidneys, and heart are working well enough for the trial.
- You are not pregnant, not breastfeeding, and agree to avoid pregnancy for 2 years after treatment.
- You have not had CAR-T therapy or other gene-modified cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called UTAA91 for people with moderate to severe rheumatoid arthritis that hasn't improved with standard treatments. The goal is to see if this treatment can help reduce symptoms and improve quality of life.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.